LINC01822

Across TCGA pan-cancer cohorts, LINC01822 RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of LINC01822’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where LINC01822 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types LINC01822 is over-expressed in tumor.

KIRC, KIRP, and LUSC are the cancer types where LINC01822 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LINC01822 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	All	All	+0.032	<.001	6	view →
KIRP	All	III,IV	+0.248	.020	3	view →
LUSC	Male	All	+0.030	.006	3	view →
KICH	Female	III,IV	+0.026	.001	2	view →
HNSC	All	All	+0.033	.033	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

LINC01822–KIRC

Open the KIRC breakdown →